The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment

Detalles Bibliográficos
Autores principales: Tran, Thai Hoa, Nguyen, Jonathan V., Stecula, Adrian, Akutagawa, Jon, Moorman, Anthony V., Braun, Benjamin S., Sali, Andrej, Mullighan, Charles G., Shah, Neil P., Dai, Yunfeng, Devidas, Meenakshi, Roberts, Kathryn G., Smith, Catherine C., Loh, Mignon L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327742/
https://www.ncbi.nlm.nih.gov/pubmed/33626861
http://dx.doi.org/10.3324/haematol.2020.261354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327742/
https://www.ncbi.nlm.nih.gov/pubmed/33626861
http://dx.doi.org/10.3324/haematol.2020.261354

Ejemplares similares